initi coverag
stock price
million per share
webcast
report limit sole use client wolf research pleas refer disclosur section locat end slide analyst
certif import disclosur disclosur
myl stock lost ytd mark materi under-perform compar drg
gain respect time period
initi market outperform rate pt impli upsid vs stock price
confid stem idea feel compani best posit
busi gener space drive earn go forward first feel busi significantli less lever toward
us price concern due signific eu footprint second feel compani success
transform busi one reli durabl biosimilar launch futur growth oppos constantli
deterior ftf gener launch lastli feel rel lower leverag compar peer lower potenti
legal liabil stem opioid litig exposur set compani success de-lev ultim
feel compani less lever toward us
price pressur peer group
think extens biosimilar portfolio set
reli durabl revenu stream go
forward compar peer
lower leverag legal liabil set
compani palat path toward de-
lever ultim earn expans
doj liabil higher expect
delay unabl launch complex gener
biosimilar product
signific eros eu intern
spec pharma one worst perform
sector healthcar last year
clear myl guilti issu
plagu sector
headlin risk epipen doj price
miss guidanc
delay key gx launch
differ come
anticip approv approv delay
billion built back complet scientif legal environ
said equiti peakit
revenu havent collaps like peer
revenu chang
acquisit meda
confid guidanc go forward base
benefit reap continu
diversif portfolio pipelin geographi
includ fact alreadi launch
product need hit billion target new
product alreadi receiv nearli
requir regulatori approv confid
hold true north america segment even
continu weather unpreced volatil
largest product epipen effect becom
generic rev op profit
gross gross oper oper estim impli estim tax tax net product us pen sold approxim us metric per pen gross oper oper net product therefor acknowledg flaw
dont model grow top-line significantli
next year year
almost imposs model compani accur
given current disclosur polici
fail give investor accur sens fx
exposur creat volatil qs
myl corpor structur unfriendli toward
sharehold ward interest
us gx base busi eros continu signific
your go invest gener long term
think one better bet
concern teva
better posit earn
rel lower debt
lead earn upsid de-
lower legal liabil doj
consist de-lever relianc
na segment made
revenu versu teva
model myl ww biosimilar portfolio bring
annual peak vs teva
ad relianc biosimilar complex gener
drive increment margin expans
model interest expens come
next year
period time see leverag
drop around
bake liabil stem
price fix investig vs teva
model liabil rel opioid case
wherea see teva incur
initi focus
legal overhang gx price fix litig
stabil base busi go forward
less lever ftf lever biosimilar
financi impact earn
done corpor govern
major headlin risk gx space
mdl creat
transfer
state file
opposit doj
motion delay
brought
doj file motion
charg
here overview
charg alleg far
class action proceed brought
group state ag state
second state ag suit alleg far
drug center around teva
alleg includ overal conspiraci
claim alleg collus gx
industri overarch meant affect
drug
seek bring joint sever
individu conspiraci involv
compani
doj investig on-going like
involv similar scope on-going civil
doj brought charg heritag
violat relat drug
exec pled guilti within day
cooper doj state
ag sourc evid
heritag pharma corp entiti
relat glyburid
remind rajiv malik explicitli
name defend state origin pf suit
sinc focu seem shift put
teva spotlight good
teva centric state complaint
imag taken new
complaint show
alleg web conspiraci
major player
that say wood still
signific amt exposur civil side
figur estim total effect im
sale start date alleg collus
earliest im datapoint whichev later
includ claim molecul total
name molecul sold
includ levothyroxin one mylan
much broader origin
complaint focus teva
name specif drug
alleg engag anti-competit
use doj sentenc guidelin well auto part
price fix civil litig estim total liabil
base abil pay model paid two
year cash flow abl absorb
flow reduc
assum payment
year start
debt rais
bridg cash
posit driven
come due first
year liabil payment
said struggl delin
problemat drug drug weaker evid
convers like satisfi doj criteria prove sherman act
reason acknowledg
calcul intent conserv
unlik drug name
complaint end creat liabil
includ everyth im analysi
drug
ashp shortag list point
alleg period shortag could lead
drug seen declin
supplier alleg period
could also lead natur price hike
doj issu fine high
 fact largest sherman act fine
citicorp
initi focus
stabil base busi go forward
less lever ftf lever biosimilar
financi impact earn
done corpor govern
rel teva myl gx portfolio
erod much less absolut sale
teva peak
may
esomeprazol mag
budesonid
methylphenid er
guanfacin hcl er
acid ethyl
divalproex sod er
celecoxib
clind phos/benz per
tolterodin tar er
fentanyl
believ that due reason
us gx base busi less competit
peer
higher
proport gx sale
stem product
sole
supplier rel peer
rapid pronounc shift
away oral drug toward inject
gx im sale inject
gx im sale inject
seen least amount
price pressur ltm
price pressur class
teva price pressur class
said still model myl
keep mind
roll anda
launch figur new
launch year
anda launch
account gx
base product
see green anda
contribut year
allow us busi stay flat/grow
margin overtim howev biosimilar portfolio
importantli myl us portfolio that
less lever toward us gx price deflat evolv
amount biosimilar
like includ
addit given geograph footprint
significantli less lever us market vs peer
move eu segment model low growth
mostli line consensu
took conserv approach
row model consensu
ultim lead rel flat
co still see earn expans
driven de-lever gross margin improv
keep mind
portion includ
addit increas
revenu also subtract
stem ad opex
margin decreas
initi focus
stabil base busi go forward
less lever ftf lever biosimilar
financi impact earn cf yield vs teva
done corpor govern
myl undergo strateg review
past year result still pend
made
chair mark
object look
altern
unlock valu
understand
think
review
committe report
near term
work done
updat may
disclos
investor day juli
didnt say
relat review
fact biggest complaint
relat management team
feedback weve heard sharehold
almost imposs model compani given current disclosur polici
